Exclusive updates on current anti-trust investigations, access to medicine and forecasts of currency fluctuations across the single market and much more at SMi's Parallel Trade Conference,
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh